Purchase this article with an account.
M. Oldani, C. Rosina, L. de Polo, M. V. Cigada, G. Staurenghi; Efficacy of Intravitreal Bevacizumab in Patients With Choroidal Neovascularization (CNV) in Angioid Streaks: Updates After Two Years Follow-Up. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2819.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy of intravitreal Bevacizumab in the treatment of CNV in patients with angioid streaks.
Retrospective chart review of 16 consecutive eyes treated with intravitreal (IVT) bevacizumab (1.25 mg) for subfoveal choroidal neovascularization secondary to angioid streaks. Five eyes underwent previously photodynamic therapy. Recurrence of CNV was confirmed by fluorescein and indocyanine green angiography. Outcome measures included visual acuity (VA), retinal thickness with OCT, and degree of leakage on fluorescein and indocyanine green angiography.Incidence rate of CNV recurrences was calculated using the Kaplan-Meier method.
Sixteen eyes of ten patients were included. The mean age was 59.3 years (range 34-78). The baseline mean VA was 0.32. After a mean follow up of 29.87 months (range 8-42), the mean VA was 0.3 and in all eyes the CNV was inactive. Five of 16 eyes (31,25%) received 1 bevacizumab IVT, four eyes (25%) 2 IVT, two eyes (12,5%) 3 IVT, one eye (6,25%) 4 IVT, two eyes (12,5%) 5 IVT, one eye (6,25%) 6 IVTand one eye (6,25%) 7 IVT. There were no systemic or ocular complications.
In our case series intravitreal Bevacizumab for CNV in angioid streaks showed a good efficacy , in particular considering that in 56,25% of cases the CNV was closed after one or two treatments. Further clinical trials are needed to evaluate a larger number of patients and a longer follow-up.
This PDF is available to Subscribers Only